Announced Wed, 17 Jun · 17:05 IST
Lupin launches Azilsartan Medoxomil Tablets in the US
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.3%1-day move
₹2278.20
prior close
₹2283.80
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.3+0.3+0.1+3.3+2.8+3.7+4.0+3.1+6.5+9.6+9.2——
Up moveDown movePending
AI summary
Lupin has launched Azilsartan Medoxomil Tablets, 40mg and 80mg, in the United States after receiving US FDA approval for its Abbreviated New Drug Application. The drug is a generic of Edarbi used to treat high blood pressure in adults. Lupin is the first-to-file, making it eligible for 180 days of exclusive generic sales in the US. The product has estimated annual US sales of about USD 53.5 million.
Likely market impact
Positive for US generics business; 180-day exclusivity may boost near-term revenue from the US segment.